Lisbeth Enggaard

Venetoclax combinations in untreated CLL: 5-year results and patient-reported outcomes analysis of the CLL13/GAIA trial

Moritz Fürstenau, Carsten Utoft Niemann, Sandra Robrecht, Emelie Rotbain et autres

de, dk, nl, ch, ie, il, fi, se, be, at (code pays fourni par la source)

Central nervous system involvement in CLL

Thomas Chatzikonstantinou, Mariia Mikhaleva, Christian Brieghel, Christina Papangelou et autres

gr, us, dk, br, ar, si (code pays fourni par la source)

Central nervous system involvement in CLL: an international retrospective study by ERIC, the European Research Initiative on CLL

Thomas Chatzikonstantinou, Mariia Mikhaleva, Christian Brieghel, Christina Papangelou et autres

gr, us, dk, br, uy, ar, cz, at, es, it, il, pl, hr, ru, au, tr, si (code pays fourni par la source)

Long term follow-up of MRD guided treatment of Ibrutinib plus Venetoclax for Relapsed CLL: phase 2 VISION/HO141 trial

Carsten Utoft Niemann, Julie Dubois, Kazem Nasserinejad, Caspar da Cunha-Bang et autres

Long-term follow-up of MRD-guided ibrutinib plus venetoclax in relapsed CLL: phase 2 VISION/HO141 trial

Carsten Utoft Niemann, Julie Dubois, Kazem Nasserinejad, Caspar da Cunha‐Bang et autres

dk, nl, be, fi, se, no (code pays fourni par la source)

Quality of Life in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Improves after Minimal Residual Disease-Guided Treatment with Ibrutinib Plus Venetoclax

Laura Eurelings, Emelie Curovic Rotbain, Sabina Kersting, Lina van der Straten et autres

nl, dk, fi, se, no (code pays fourni par la source)

First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial

Moritz Fürstenau, Arnon P. Kater, Sandra Robrecht, Julia von Tresckow et autres

de, nl, ch, ie, at, il, fi, se, be, dk (code pays fourni par la source)

Supplementary Table S3 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials

Rebecca Svanberg Teglgaard, Hanne Vibeke Marquart, Hans Jakob Hartling, Jakob Thaning Bay et autres

Supplementary Figure S3 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials

Rebecca Svanberg Teglgaard, Hanne Vibeke Marquart, Hans Jakob Hartling, Jakob Thaning Bay et autres

Supplementary Figure S1 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials

Rebecca Svanberg Teglgaard, Hanne Vibeke Marquart, Hans Jakob Hartling, Jakob Thaning Bay et autres

Supplementary Table S4 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials

Rebecca Svanberg Teglgaard, Hanne Vibeke Marquart, Hans Jakob Hartling, Jakob Thaning Bay et autres

Supplementary Table S4 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials

Rebecca Svanberg Teglgaard, Hanne Vibeke Marquart, Hans Jakob Hartling, Jakob Thaning Bay et autres